Before even going into Phase II trials, Theravance Biopharma Inc. has bagged the biggest player in inflammatory bowel disease – Johnson & Johnson – as a partner for its pan-Janus kinase (JAK) inhibitor which the firm is already talking about as a transformational treatment for ulcerative colitis and Crohn's disease.
It is a big deal too, with Theravance getting an upfront payment of $100m from J&J's Janssen unit for TD-1473,...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
